For patients and healthcare providers in the United States, you can learn more about Oxbryta by visiting the product website or downloading the full U.S. prescribing information.
About GBT
GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.
GBT Supports
Latest News
02-26-20 GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2019 Financial Results02-25-20 GBT Announces Participation at the Cowen and Company 40th Annual Healthcare Conference02-20-20 GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Disease
more news »